Log in

Relevant bibliographies by topics / Extracellular vesicle-based therapies

Contents

Journal articles

Academic literature on the topic 'Extracellular vesicle-based therapies'

Author: Grafiati

Published: 4 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Extracellular vesicle-based therapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Extracellular vesicle-based therapies"

1

Wang, Ziqi, Haonan Xing, Yuanyu Huang, and Mei Lu. "Extracellular vesicle-based targeted RNA therapies against cancer." Extracellular Vesicle 6 (December 2025): 100083. https://doi.org/10.1016/j.vesic.2025.100083.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Amengual-Tugores, Andreu Miquel, Carmen Ráez-Meseguer, Maria Antònia Forteza-Genestra, Marta Monjo, and Joana M. Ramis. "Extracellular Vesicle-Based Hydrogels for Wound Healing Applications." International Journal of Molecular Sciences 24, no. 4 (2023): 4104. http://dx.doi.org/10.3390/ijms24044104.

Full text

Abstract:

Hydrogels and extracellular vesicle-based therapies have been proposed as emerging therapeutic assets in wound closure. The combination of these elements has given good results in managing chronic and acute wounds. The intrinsic characteristics of the hydrogels in which the extracellular vesicles (EVs) are loaded allow for overcoming barriers, such as the sustained and controlled release of EVs and the maintenance of the pH for their conservation. In addition, EVs can be obtained from different sources and through several isolation methods. However, some barriers must be overcome to transfer t

APA, Harvard, Vancouver, ISO, and other styles

3

Miura, Yasuo, Sumie Fujii, and Tatsuo Ichinohe. "Cell-based and extracellular vesicle-based MSC therapies for acute radiation syndrome affecting organ systems." Journal of Radiation Research 65, Supplement_1 (2024): i80—i87. https://doi.org/10.1093/jrr/rrae009.

Full text

Abstract:

Abstract Exposure to ionizing radiation can induce harmful biological effects on the human body, particularly in cases of high-dose γ-irradiation affecting the gastrointestinal tract, bone marrow, skin and lung. Such exposures lead to lethal outcomes as individuals experience a breakdown in their immune system’s ability to defend against pathogens, predisposing them to sepsis-induced multiple organ failures. Mesenchymal stromal/stem cells (MSCs) possess diverse biological characteristics, including immunomodulation, anti-inflammation and tissue regeneration. Off-the-shelf culture-expanded huma

APA, Harvard, Vancouver, ISO, and other styles

4

Drohat, Philip, Max Baron, Lee D. Kaplan, Thomas M. Best, and Dimitrios Kouroupis. "Long-Acting Extracellular Vesicle-Based Biologics in Osteoarthritis Immunotherapy." Bioengineering 12, no. 5 (2025): 525. https://doi.org/10.3390/bioengineering12050525.

Full text

Abstract:

Osteoarthritis (OA) is a chronic degenerative joint disease characterized by low-grade inflammation, cartilage breakdown, and persistent pain. Despite its prevalence, current therapeutic strategies primarily focus on symptom management rather than modifying disease progression. Monoclonal antibodies and cytokine inhibitors targeting inflammatory pathways, including TNF-α and IL-1, have shown promise but remain limited by inconsistent efficacy and safety concerns. Long-acting biologic therapies—ranging from extended-release formulations, such as monoclonal antibodies and cytokine inhibitors, to

APA, Harvard, Vancouver, ISO, and other styles

5

Massoumi, Hamed, Sohil Amin, Mohammad Soleimani, et al. "Extracellular-Vesicle-Based Therapeutics in Neuro-Ophthalmic Disorders." International Journal of Molecular Sciences 24, no. 10 (2023): 9006. http://dx.doi.org/10.3390/ijms24109006.

Full text

Abstract:

Extracellular vesicles (EVs) have been recognized as promising candidates for developing novel therapeutics for a wide range of pathologies, including ocular disorders, due to their ability to deliver a diverse array of bioactive molecules, including proteins, lipids, and nucleic acids, to recipient cells. Recent studies have shown that EVs derived from various cell types, including mesenchymal stromal cells (MSCs), retinal pigment epithelium cells, and endothelial cells, have therapeutic potential in ocular disorders, such as corneal injury and diabetic retinopathy. EVs exert their effects th

APA, Harvard, Vancouver, ISO, and other styles

6

Chen, Ao, Hengli Tian, Nana Yang, et al. "Towards extracellular vesicle delivery systems for tissue regeneration: material design at the molecular level." Extracellular Vesicles and Circulating Nucleic Acids 3, no. 4 (2022): 306–39. http://dx.doi.org/10.20517/evcna.2022.37.

Full text

Abstract:

The discovery and development of extracellular vesicles in tissue engineering have shown great potential for tissue regenerative therapies. However, their vesicle nature requires dosage-dependent administration and efficient interactions with recipient cells. Researchers have resorted to biomaterials for localized and sustained delivery of extracellular vesicles to the targeted cells, but not much emphasis has been paid on the design of the materials, which deeply impacts their molecular interactions with the loaded extracellular vesicles and subsequent delivery. Therefore, we present in this

APA, Harvard, Vancouver, ISO, and other styles

7

Wang, Baihui, Amanda Moyano, José María Duque, et al. "Nanozyme-Based Lateral Flow Immunoassay (LFIA) for Extracellular Vesicle Detection." Biosensors 12, no. 7 (2022): 490. http://dx.doi.org/10.3390/bios12070490.

Full text

Abstract:

Extracellular vesicles (EVs) are biological nanoparticles of great interest as novel sources of biomarkers and as drug delivery systems for personalized therapies. The research in the field and clinical applications require rapid quantification. In this study, we have developed a novel lateral flow immunoassay (LFIA) system based on Fe3O4 nanozymes for extracellular vesicle (EV) detection. Iron oxide superparamagnetic nanoparticles (Fe3O4 MNPs) have been reported as peroxidase-like mimetic systems and competent colorimetric labels. The peroxidase-like capabilities of MNPs coated with fatty aci

APA, Harvard, Vancouver, ISO, and other styles

8

Hagedorn, Lasse, David C. Jürgens, Olivia M. Merkel, and Benjamin Winkeljann. "Endosomal escape mechanisms of extracellular vesicle-based drug carriers: lessons for lipid nanoparticle design." Extracellular Vesicles and Circulating Nucleic Acids 5, no. 3 (2024): 344–57. http://dx.doi.org/10.20517/evcna.2024.19.

Full text

Abstract:

The rise of biologics and RNA-based therapies challenges the limitations of traditional drug treatments. However, these potent new classes of therapeutics require effective delivery systems to reach their full potential. Lipid nanoparticles (LNPs) have emerged as a promising solution for RNA delivery, but endosomal entrapment remains a critical barrier. In contrast, natural extracellular vesicles (EVs) possess innate mechanisms to overcome endosomal degradation, demonstrating superior endosomal escape (EE) compared to conventional LNPs. This mini review explores the challenges of EE for lipid

APA, Harvard, Vancouver, ISO, and other styles

9

Yerneni, Saigopalakrishna, Juliana Hofstatter Azambuja, Daria Strelkova-Petersen, et al. "DDEL-01. ENGINEERING MRNA THERAPIES FOR BRAIN TUMORS." Neuro-Oncology 26, Supplement_8 (2024): viii121. http://dx.doi.org/10.1093/neuonc/noae165.0468.

Full text

Abstract:

Abstract Safe delivery of mRNA to the brain will revolutionize the treatment of brain tumors. While lipid nanoparticles (LNPs) are clinically most advanced non-viral delivery vehicles for therapeutic mRNA, LNP-mediated mRNA delivery to the brain remains challenging. We hypothesized that rationally designed LNPs based on extracellular vesicle mimicry would enable efficient delivery of RNA therapeutics to brain cells without undue toxicity. We engineered LNPs consisting of four components similar to the formulation used in the mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech): ionizable lipid

APA, Harvard, Vancouver, ISO, and other styles

10

Ceja, Lourdes, Sean S. Escopete, Lorelei Hughes, et al. "Neonatal Cardiovascular-Progenitor-Cell-Derived Extracellular Vesicles Activate YAP1 in Adult Cardiac Progenitor Cells." International Journal of Molecular Sciences 24, no. 9 (2023): 8088. http://dx.doi.org/10.3390/ijms24098088.

Full text

Abstract:

New stem cell and extracellular-vesicle-based therapies have the potential to improve outcomes for the increasing number of patients with heart failure. Since neonates have a significantly enhanced regenerative ability, we hypothesized that extracellular vesicles isolated from Islet-1+ expressing neonatal human cardiovascular progenitors (CPCs) will induce transcriptomic changes associated with improved regenerative capability when co-cultured with CPCs derived from adult humans. In order to test this hypothesis, we isolated extracellular vesicles from human neonatal Islet-1+ CPCs, analyzed th

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!